- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2424EUR$2,789USD£2,110GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2424EUR$2,789USD£2,110GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2424EUR$2,789USD£2,110GBP
- Report
- September 2025
- 150 Pages
Global
From €3346EUR$3,850USD£2,912GBP
€4215EUR$4,850USD£3,668GBP
- Report
- March 2025
- 150 Pages
Global
From €3346EUR$3,850USD£2,912GBP
€4215EUR$4,850USD£3,668GBP
- Report
- February 2025
- 150 Pages
Global
From €3346EUR$3,850USD£2,912GBP
€4215EUR$4,850USD£3,668GBP
- Report
- July 2025
- 150 Pages
Global
From €3346EUR$3,850USD£2,912GBP
€4215EUR$4,850USD£3,668GBP
- Report
- May 2025
- 82 Pages
Global
From €3500EUR$4,314USD£3,153GBP
- Report
- September 2025
- 150 Pages
Global
From €3867EUR$4,450USD£3,366GBP
- Report
- April 2025
- 130 Pages
Global
From €4215EUR$4,850USD£3,668GBP
- Report
- February 2026
Global
From €450EUR$555USD£405GBP
- Report
- December 2024
- 90 Pages
Global
From €1356EUR$1,560USD£1,180GBP
€2086EUR$2,400USD£1,815GBP
- Report
- November 2024
- 600 Pages
Global
From €1864EUR$2,145USD£1,622GBP
€2868EUR$3,300USD£2,496GBP
- Report
- December 2024
- 100 Pages
Global
From €5171EUR$5,950USD£4,501GBP
- Report
- June 2024
- 300 Pages
Global
From €2129EUR$2,450USD£1,853GBP
- Report
- March 2022
- 182 Pages
Global
From €2281EUR$2,625USD£1,986GBP
€4563EUR$5,250USD£3,971GBP
- Report
- January 2025
- 175 Pages
Global
From €3902EUR$4,490USD£3,396GBP
- Report
- January 2025
- 175 Pages
Global
From €3902EUR$4,490USD£3,396GBP
- Report
- January 2025
- 175 Pages
Global
From €3902EUR$4,490USD£3,396GBP
- Drug Pipelines
- September 2024
- 247 Pages
Global
From €6909EUR$7,950USD£6,013GBP
Neuroendocrine carcinoma (NEC) is a rare type of cancer that affects the neuroendocrine system, which is responsible for the production of hormones. It is a type of cancer that is often difficult to diagnose and treat. Treatment options for NEC include surgery, chemotherapy, radiation therapy, and targeted therapies. Oncology drugs are used to treat NEC, and they can be used alone or in combination with other treatments. These drugs can help to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of recurrence.
The Neuroendocrine Carcinoma market is a rapidly growing segment of the oncology drugs market. It is driven by the increasing prevalence of NEC, the development of new treatments, and the increasing availability of targeted therapies. Companies in the market include Novartis, Pfizer, Merck, AstraZeneca, and Roche. Show Less Read more
